Temperini Claudia, Cecchi Alessandro, Scozzafava Andrea, Supuran Claudiu T
Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy.
Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24.
Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide. Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM). Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV. Examining the four X-ray crystal structures of their CA II adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity. Indeed, indapamide bound to CA II has no interactions with active site water molecules. Chlorthalidone bound within the CA II active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong hydrogen bonds with Asn67 and a water molecule. The newly evidenced binding modes of these diuretics may be exploited for designing better CA II inhibitors as well as compounds with selectivity/affinity for various isoforms with medicinal chemistry applications.
噻嗪类和高效能利尿剂最近被证明可抑制碳酸酐酶(CA,EC 4.2.1.1)的所有哺乳动物同工型,与经典抑制剂如乙酰唑胺、甲醋唑胺和乙氧唑胺相比,其作用模式有很大不同。这些结构相关的化合物中,有些对广泛存在的同工酶CA II表现出非常不同的行为,氯噻酮、三氯噻嗪和呋塞米是CA II的有效抑制剂(抑制常数K(I)为65 - 138 nM),而吲达帕胺的抑制作用则弱得多(K(I)为2520 nM)。此外,其中一些利尿剂是其他同工型的高效(低纳摩尔级)抑制剂,例如氯噻酮对hCA VB、VII、IX和XIII;吲达帕胺对CA VII、IX、XII和XIII,三氯噻嗪对CA VII和IX,以及呋塞米对CA I和XIV。通过研究它们与CA II加合物的四个X射线晶体结构,我们观察到有几个(2 - 3个)活性位点水分子与氯噻酮、三氯噻嗪和呋塞米的支架相互作用,这可能是造成这种重要活性差异的原因。实际上,与CA II结合的吲达帕胺与活性位点水分子没有相互作用。结合在CA II活性位点内的氯噻酮呈烯醇式(内酰胺式)互变异构形式,烯醇式OH还与Asn67和一个水分子形成两个强氢键。这些利尿剂新发现的结合模式可用于设计更好的CA II抑制剂以及对各种同工型具有选择性/亲和力的化合物,以应用于药物化学领域。